MedTrace Logo

SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer

NCT01542294 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2016-06-14

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of S-1 plus oxaliplatin combination chemotherapy based on the adverse events and survival period by performing a phase I/II study of this combination in patients with D2 resection of gastric cancer.

Conditions

Interventions

DRUG

s1

60-90mg/m2/d P.O. day 1-14, repeated every 21 days

DRUG

Oxaliplatin

130mg/m2 d1 repeated every 21 days

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Lin Yang, MD · Department of Medical Oncology,Cancer Hospital and Institute,CAMS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-09-30
Completion
2017-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01542294 on ClinicalTrials.gov